Literature DB >> 25590009

Rare and persistent Rhodococcus equi infection in a diffuse large B cell lymphoma patient: case report and review of the literature.

Junli Zhang1, Jing Xu1, Xiaoxing Du1, Yunsong Yu1, Fangfang Lv1.   

Abstract

Rhodococcus equi (R. equi) is an uncommon gram positive organism. It is a rare but recognized pathogen in humans and has emerged as an important cause of morbidity and mortality among immunocompromised patients. Generally, R. equi infection needs combined treatment with effective antibiotics, and often requires the immune adjuvant therapy. Here we reported a 49-year-old man presented dyspnea with fever, skin ulcer for 5 months, and the final diagnosis was diffuse large B cell lymphoma with R. equi septicemia and pneumonia, the treatment was failure, the blood culture was always positive during the course of disease, though he was given combined treatment with effective antibiotics, perhaps the immune reconstitution or immune supportive treatment was more important.

Entities:  

Keywords:  Rhodococcus equi (R. equi); combined treatment; diffuse large B cell lymphoma; immunologic reconstitution

Year:  2014        PMID: 25590009      PMCID: PMC4283301          DOI: 10.3978/j.issn.2072-1439.2014.12.17

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  20 in total

1.  Rhodococcus equi infection after lung transplantation.

Authors:  Don Hayes; Enrique Diaz-Guzman; Charles W Hoopes
Journal:  Respir Care       Date:  2011-04-19       Impact factor: 2.258

2.  Nonhealing wound due to Rhodococcus equi in an apparently immunocompetent patient, revealing CD8+ T-lymphocyte deficiency.

Authors:  Eric Denes; Dominique Peignon-Orsoni; François-Xavier Terrade
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

Review 3.  Trans-thoracic biopsy of lung lesions: FNAB or CNB? Our experience and review of the literature.

Authors:  Emanuela Capalbo; Michela Peli; Maria Lovisatti; Maria Cosentino; Paola Mariani; Eisabetta Berti; Maurizio Cariati
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

4.  Infectious pseudotumors: red herrings in head and neck pathology.

Authors:  Samir K El-Mofty; Shreeram Akilesh
Journal:  Head Neck Pathol       Date:  2012-03-20

5.  Rhodococcus equi: an emerging pathogen.

Authors:  David M Weinstock; Arthur E Brown
Journal:  Clin Infect Dis       Date:  2002-04-25       Impact factor: 9.079

6.  Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases.

Authors:  Manuel Torres-Tortosa; Julio Arrizabalaga; José L Villanueva; Juan Gálvez; María Leyes; M Eulalia Valencia; Juan Flores; José M Peña; Elisa Pérez-Cecilia; Carmen Quereda
Journal:  Chest       Date:  2003-06       Impact factor: 9.410

7.  Interactions between endocarditis-derived Streptococcus gallolyticus subsp. gallolyticus isolates and human endothelial cells.

Authors:  Tanja Vollmer; Dennis Hinse; Knut Kleesiek; Jens Dreier
Journal:  BMC Microbiol       Date:  2010-03-16       Impact factor: 3.605

8.  Virulence of Rhodococcus equi isolates from patients with and without AIDS.

Authors:  S Takai; Y Sasaki; T Ikeda; Y Uchida; S Tsubaki; T Sekizaki
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

9.  Primary retroperitoneal abscesses due to Rhodococcus equi in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline.

Authors:  Gianluca Russo; Miriam Lichtner; Martina Carnevalini; Maria Teresa Mascellino; Fabio Mengoni; Alessandra Oliva; Ginevra Azzurra Miccoli; Marco Iannetta; Vito Trinchieri; Anna Paola Massetti; Claudio Maria Mastroianni; Vincenzo Vullo
Journal:  Int J Infect Dis       Date:  2009-09-15       Impact factor: 3.623

10.  Disseminated Rhodococcus equi infection in HIV infection despite highly active antiretroviral therapy.

Authors:  Francesca Ferretti; Antonio Boschini; Cristiana Iabichino; Simonetta Gerevini; Paola De Nardi; Monica Guffanti; Giuseppe Balconi; Adriano Lazzarin; Paola Cinque
Journal:  BMC Infect Dis       Date:  2011-12-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.